Deciphering the Molecular Structure of the Type III Secretion System in Chlamydia trachomatis for Structure-Based Therapeutic Targeting

Chlamydia trachomatis is an obligate intracellular Gram-negative pathogen responsible for sexually transmitted infections and trachoma in humans. Although antibiotics are generally effective against acute infections, persistent chlamydial forms often exhibit reduced susceptibility during chronic infection. Chlamydia relies on its type III secretion system (T3SS) to inject effector proteins into host cells, making T3SS proteins attractive targets for antivirulence therapeutics. In this study, we employed an integrated computational pipeline to model and assemble the C. trachomatis T3SS constituent proteins. Template-based modeling using crystallographic structures of homologs from other Gram-negative bacteria revealed a highly conserved structural architecture despite low sequence identity (18-46%). Stereochemical validation confirmed high model quality, with most T3SS proteins exhibiting favorable protein-protein interactions (PPIs). Since the activity of the T3SS complex relies on extensive PPIs, we targeted these PPIs as a promising approach to attenuate bacterial virulence. CdsN, which functions as an ATPase of the T3SS, is a hexamer of which we targeted the dimerization interface. Structure-based virtual screening of compounds from the e-Drug3D and IMPPAT libraries against predicted hotspot residues and the identified druggable pocket at the CdsN dimeric interface, followed by ADMET screening, yielded three promising candidates: M Roflumilast (Drug ID: 1537), Elacestrant (Drug ID: 2081), and Tecovirimat (Drug ID: 1889). All three ligands formed thermodynamically stable complexes with the CdsN dimer, with Elacestrant demonstrating the most favourable binding free energy. This was also confirmed by 100 ns molecular dynamics simulation. This study provides new insights into the molecular architecture of C. trachomatis T3SS and identifies M Roflumilast, Elacestrant, and Tecovirimat as potential drug candidates against chlamydial infection.